As Americans continue to struggle to afford their medical bills, and some newly insured under the Affordable Care Act find they can’t afford to use the coverage they purchased, finding the “right” health insurance plan is important.
As Americans continue to struggle to afford their medical bills, and some newly insured under the Affordable Care Act find they can’t afford to use the coverage they purchased, finding the “right” health insurance plan is important.
The University of Michigan Center for Value-Based Insurance Design, led by A. Mark Fendrick, MD, director of the center and co-editor-in-chief of The American Journal of Managed Care, has released a new whiteboard video highlighting the benefits of a value-based insurance design (VBID) plan.
In the video, Goldilocks Choose a Health Plan, the titular character tries out a health plan that is “too soft,” which may cover many services, have a broad provider network, and include low cost-sharing, but also encourages wasteful spending and will be subject to the Cadillac tax. She also looks at a plan that is “too hard,” with high deductibles, narrow networks, and few covered services before the deductible and which could worsen health disparities and lead to adverse health outcomes.
The VBID plan ends up being “just right” by lowering cost-sharing for high-value services, discouraging use of services with no proven value, and an affordable price. Watch the full video from the VBID Center.
Recently, CMS announced that it would be holding a 5-year demonstration in 7 states of VBID in Medicare Advantage.
“The 5-year model will look, at the end, to see if lowering cost-sharing for high-value services and providers will meet the triple aim of better quality of care, better patient experience, and lower healthcare costs,” explained Dr Fendrick.
He also outlined that some of the hurdles that need to be overcome with the demonstration are concerns about who will enroll and if people understand and take advantage of the lower cost-sharing.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More